股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州九源基因生物醫藥股份有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02566 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 109,096,785 | RMB | | 1 RMB | | 109,096,785 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 109,096,785 | RMB | | 1 RMB | | 109,096,785 | | 2. 股份分類 | 普通股 | 股份類別 | 其他 ...

九源基因(02566)绩后涨超7%，截至发稿，涨7.02%，报15.4港元，成交额1024.28万港元。 截至2025年6月30日，公司实现收入总额同比下降9.1%，期内溢利同比下降14.4%。上半年收入总额小 幅下滑主要受内外部因素综合影响。 消息面上，8月19日，九源基因发布截至2025年6月30日止6个月的中期业绩，该集团取得收益人民币 6.39亿元(单位下同)，同比下降9.05%；毛利5.25亿元，同比下降2.84%；母公司股东应占纯利9017.4万 元，同比下降14.4%；每股盈利0.37元。 本报告期内，公司骨科领域产品销量同比增长超过10%，医院渗透率持续提升。围绕公司全年经营目 标，以稳定现有市场和培育增量市场为着力点实施差异化商业政策，争取实现全年业务收入的平稳增 长。 ...

Core Viewpoint - Jiuyuan Gene (02566) experienced a stock price increase of over 7% following the release of its interim results, indicating market optimism despite a decline in financial performance [1] Financial Performance - For the six months ending June 30, 2025, Jiuyuan Gene reported revenue of RMB 639 million, a year-on-year decrease of 9.05% [1] - Gross profit was RMB 525 million, down 2.84% year-on-year [1] - Net profit attributable to shareholders was RMB 90.17 million, reflecting a decline of 14.4% compared to the previous year [1] - Earnings per share stood at RMB 0.37 [1] Market Dynamics - The overall revenue decline of 9.1% was attributed to a combination of internal and external factors [1] - Sales of orthopedic products increased by over 10% year-on-year, indicating growth in this segment [1] - The company is focusing on stabilizing existing markets and cultivating new ones through differentiated commercial policies to achieve steady annual revenue growth [1]

Core Viewpoint - The significant rise of Jiuyuan Gene (02566) in the Hong Kong biotech sector, with a price increase of over 218% from a low of 5.119 HKD to a peak of 16.29 HKD, driven by the anticipation of its GLP-1 drug, Semaglutide biosimilar (JY29-2), which is expected to submit a drug application in the first half of 2026 [1][20]. Group 1: Company Performance and Market Dynamics - Jiuyuan Gene's market capitalization surpassed 30 billion HKD during this surge, indicating strong investor interest and market confidence [1]. - The company plans to enhance its market presence by leveraging hospital networks and e-commerce partnerships to improve accessibility and brand recognition [1]. - The stock experienced a classic trading pattern characterized by accumulation, distribution, and subsequent price surges, reflecting a strategic capital game [1][20]. Group 2: Trading Phases and Price Movements - The trading phases included a "building position" period from November 28, 2024, to January 17, 2025, where the stock saw a price drop of 26.62% and a high volatility of 52.7% [2][5]. - The "first surge" phase from January 20 to February 21, 2025, recorded a 30.04% increase, indicating strong market support despite low trading volume [7][8]. - The "main surge" phase from June 5 to June 12, 2025, saw a dramatic 72.08% increase, showcasing aggressive buying behavior and a lack of selling pressure [11][12]. Group 3: Strategic Partnerships and Market Potential - Jiuyuan Gene has secured exclusive licensing agreements for Semaglutide in key international markets, including partnerships with Kexing Bio and Fosun Pharma, which are expected to enhance its market reach [18]. - The GLP-1 drug market is projected to grow significantly, with estimates suggesting a potential market size exceeding 150 billion USD by 2030, highlighting the strategic importance of Jiuyuan Gene's product offerings [19][20]. Group 4: Investor Sentiment and Market Trends - Recent reports from multiple brokerages express positive sentiment towards weight-loss concept stocks, indicating a growing interest in the GLP-1 sector as a new investment frontier [19]. - The rise in Jiuyuan Gene's stock price is attributed to a combination of product growth potential, favorable market conditions, and a reassessment of its valuation, reflecting a broader trend in the biotech industry [20].

Core Viewpoint - The significant rise of Jiuyuan Gene (02566) in the Hong Kong biotech sector, with a price increase of over 218% from a low of 5.119 HKD to a peak of 16.29 HKD, driven by the anticipation of the market launch of its GLP-1 drug, JY29-2, in 2026 [1][20]. Company Overview - Jiuyuan Gene specializes in GLP-1 drugs and is preparing to submit a drug application for its biosimilar, Semaglutide, in the first half of 2026 [1][18]. - The company has entered into exclusive licensing agreements for Semaglutide with other domestic pharmaceutical companies, expanding its market reach in Latin America and the Middle East [18]. Market Dynamics - The biotech sector is experiencing a surge in interest, particularly in the GLP-1 drug market, which is projected to exceed 150 billion USD by 2030, indicating a strong growth potential [19]. - Recent reports from multiple brokerages express optimism about weight-loss concept stocks, highlighting the GLP-1 sector as a new capital favorite [19]. Investment Behavior - The stock price movements of Jiuyuan Gene reflect a classic investment strategy involving accumulation, consolidation, and subsequent price increases, characterized by significant volatility and strategic selling [1][9][20]. - The stock saw a massive public offering with a subscription rate of 675.83 times, leading to a high retail investor ownership and a lack of institutional support [2][3]. Trading Phases - The trading phases of Jiuyuan Gene include a "building position" phase characterized by high volatility, a "washing" phase to rebalance shares, and a "main rising wave" phase where the stock price surged dramatically [1][9][10]. - The stock experienced a significant drop of 26.62% during the initial accumulation phase, followed by a 30.04% increase in the first rally phase, indicating a controlled accumulation strategy by major investors [4][7]. Recent Performance - The stock's recent performance includes a notable rebound from 7.85 HKD to 10.58 HKD, followed by a second main rising wave that saw the price increase by 53.88% [13][15]. - The trading volume and price movements suggest a high level of control by major investors, with significant buying activity during price dips and strategic selling at peaks [10][12][20].

Group 1 - The company reported a revenue of RMB 639 million for the six months ending June 30, 2025, representing a year-on-year decline of 9.05% [1] - Gross profit was RMB 525 million, down 2.84% year-on-year, while net profit attributable to shareholders was RMB 90.17 million, a decrease of 14.4% [1] - The decline in revenue was attributed to both internal and external factors, including intensified national healthcare cost control measures and adjustments in drug pricing policies [1] Group 2 - The company experienced over 10% year-on-year growth in sales of orthopedic products, with an increasing hospital penetration rate [2] - The company aims for stable revenue growth by implementing differentiated commercial policies and enhancing professional academic promotion in the orthopedic market [2] - The company is focused on expanding its research and development pipeline in the fields of metabolism, orthopedics, oncology, and hematology, including multiple innovative drugs and biosimilars [2]

本报告期内，公司骨科领域产品销量同比增长超过10%，医院渗透率持续提升。围绕公司全年经营目 标，我们以稳定现有市场和培育增量市场为着力点实施差异化商业政策，争取实现全年业务收入的平稳 增长。针对现有市场，继续坚持以专业学术推广为引领，多层次组织开展丰富的骨科产品交流、学术沙 龙、院间交流会;提升业务人员专业水平，提升骨科产品医院市场稳定性;加强对骨科产品的全周期管 理，除了骨科治疗服务，拓展术后康复、术后护理等服务。针对增量市场，扩充队伍增加空白地县级医 院覆盖;积极组织参与全国性和区域性的学术会议，提高对基层医生技术水平的深度培训，促进对公司 骨科产品的认识;积极推进省级医保目录的全面覆盖，提升产品竞争力。 充分运用现有技术平台，我们致力于代谢、骨科、肿瘤及血液领域创新产品的开发。截至本公告日期， 本公司在前述领域布局了丰富的研发管线，其中包括多个创新药、生物类似药和生物药械组合产品。 智通财经APP讯，九源基因(02566)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益人民币 6.39亿元(单位下同)，同比下降9.05%;毛利5.25亿元，同比下降2.84%;母公司股东应占纯利9017.4 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 – 2 – 管理層討論及分析 HANGZHOU JIUYUAN GENETIC BIOPHARMACEUTICAL CO., LTD. 杭州九源基因生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2566） 截 至2025年6月30日止六個月之中期業績公告 杭州九源基因生物醫藥股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）董 事（「董 事」）會（「董事會」）欣然公佈本集團截至2025年6月30日止六個月（「報 告 期」）之 未 經 審 核 綜 合 中 期 業 績，連 同 截 至2024年6月30日止六個月（「同 期」）的 比 較 數 字。本 集 團 於 報 告 期 的 綜 合 中 期 財 務 報 表 已 由 董 事 會 及 審 核 委 員 會 審 ...

Core Viewpoint - Jiuyuan Gene (02566) saw a nearly 24% increase in stock price, attributed to the upcoming board meeting to approve mid-term performance and the potential of its biosimilar drug Semaglutide in the domestic market [1] Company Developments - Jiuyuan Gene's stock rose by 23.72% to HKD 15.28, with a trading volume of HKD 41.215 million [1] - The company plans to hold a board meeting on August 18 to approve its mid-term performance [1] - Jiuyuan Gene is focusing on the metabolic field, particularly with its potential first domestic biosimilar of Semaglutide [1] Market Strategy - The company aims to leverage its first-mover advantage in the hospital market and expand accessibility through pharmacy networks and strategic partnerships with e-commerce platforms [1] - Jiuyuan Gene has granted overseas rights for Semaglutide to other domestic pharmaceutical companies, including a unique licensing agreement with Sinovac Biotech for major Latin American countries [1] - A product licensing agreement with Fosun Pharma allows them exclusive rights for clinical development, registration, and commercialization of Semaglutide and other products in the Middle East, North Africa, sub-Saharan Africa, and parts of ASEAN countries [1] - New drug applications for Semaglutide are expected to be submitted to Brazil and Saudi Arabia by 2025 [1]

Group 1 - Jiuyuan Gene (02566) saw a nearly 24% increase in stock price, reaching HKD 15.28 with a trading volume of HKD 41.215 million [1] - The company plans to hold a board meeting on August 18 to approve its interim results, which is a significant upcoming event [1] - Jiuyuan Gene is focused on the development of the first domestic biosimilar of Semaglutide, with weight loss indications expected to be submitted for market approval in the first half of 2026 [1] Group 2 - The company aims to strengthen its market presence by enhancing its hospital market advantages and expanding accessibility through pharmacy networks and e-commerce partnerships [1] - Jiuyuan Gene has granted overseas rights for Semaglutide to other domestic pharmaceutical companies, including exclusive licensing agreements with Kexing Bio for major Latin American countries and Fosun Pharma for various regions including the Middle East and parts of Africa [1] - New drug applications for Semaglutide are expected to be submitted in Brazil and Saudi Arabia by 2025 [1]